Good COVID-19 Related Products – 3,6-Difluoropyrazine-2-Carbonitrile CAS 356783-28-3 Favipiravir Intermediate COVID-19 – Ruifu

Manufacturer with High Purity and Stable Quality Commercial Supply Favipiravir (CAS: 259793-96-9) and Related Intermediates: Favipiravir CAS: 259793-96-9 3,6-Dichloropyrazine-2-carbonitrile CAS: 356783-16-9 3,6-Difluoropyrazine-2-carbonitrile CAS: 356783-28-3 6-Bromo-3-hydroxypyrazine-2-carboxamide CAS: 259793-88-9 3-Hydroxypyrazine-2-Carboxamide CAS: 55321-99-8 2-Aminopropanediamide CAS: 62009-47-6 Diethyl Aminomalonate Hydrochloride CAS: 13433-00-6

Chemical Name	3,6-Difluoropyrazine-2-Carbonitrile
CAS Number	356783-28-3
CAT Number	RF-PI227
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C5HF2N3
Molecular Weight	141.08
Brand	Ruifu Chemical

Item	Specifications
Appearance	Pale Yellow to Off-White Powder
Purity	≥98.0%
Loss on Drying	≤1.0%
Residue on ignition	≤0.5%
Test Standard	Enterprise Standard
Usage	Pharmaceutical Intermediates; Favipiravir (CAS: 259793-96-9) Intermediate

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation. 3,6-Difluoropyrazine-2-Carbonitrile CAS: 356783-28-3 is an intermediate of Favipiravir (CAS: 259793-96-9). Favipiravir (CAS: 259793-96-9) in the treatment of Influenza virus infections. Favipiravir, also known as Favilavir, T705, or Avigan, is a selective inhibitor of viral RNA-dependent RNA polymerase with activity against many RNA viruses, influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses and alphaviruses. Activity against enteroviruses and Rift Valley fever virus has also been demonstrated. The mechanism of its actions is thought to be related to the selective inhibition of viral RNA-dependent RNA polymerase. Favipiravir does not inhibit RNA or DNA synthesis in mammalian cells and is not toxic to them. In 2014, favipiravir was approved in Japan for stockpiling against influenza pandemics.